The IRS is considering a shift that would make it easier for pharmaceutical, technology and other companies to spin off high-risk units without tax consequences—and raising the prospect of further c…
The IRS is considering a shift that would make it easier for pharmaceutical, technology and other companies to spin off high-risk units without tax consequences—and raising the prospect of further c…